Studies on the effect of allicin (diallyl disulphide-oxide) on alloxan diabetes. I. Hypoglycaemic action and enhancement of serum insulin effect and glycogen synthesis.
D000284:Administration, Oral; D000498:Allyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D005737:Garlic; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood*; D008099:Liver / Q000378:metabolism; D008112:Liver Glycogen / Q000096:biosynthesis*; D008297:Male; D010946:Plants, Medicinal; D051381:Rats; D013441:Sulfinic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D014044:Tolbutamide / Q000627:therapeutic use
D000498:Allyl Compounds; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D013441:Sulfinic Acids; D014044:Tolbutamide